Adult asthma and gastro‐oesophageal reflux: the effects of omeprazole therapy on asthma
- 1 October 1996
- journal article
- clinical trial
- Published by Wiley in Australian and New Zealand Journal of Medicine
- Vol. 26 (5) , 671-676
- https://doi.org/10.1111/j.1445-5994.1996.tb02938.x
Abstract
Approximately 40-60% of patients with asthma have gastro-oesophageal reflux (GOR) and it has been postulated that this may worsen asthma severity. To investigate the effect of the potent gastric acid inhibitor omeprazole 40 mg orally daily on peak expiratory flow rate (PEFR), asthma symptoms and histamine bronchial responsiveness in adult patients with both asthma and GOR. This was a double blind, randomised, placebo controlled, crossover study. Upper gastrointestinal endoscopy, 24 hour oesophageal pH measurements, spirometry and histamine bronchoprovocation test (HIT) were performed prior to entry. Phase 1:2 week placebo run-in period, with baseline recording of PEFR, asthma and GOR symptoms, and use of inhaled beta 2-agonist. Phase 2: patients randomised to receive either placebo or omeprazole 40 mg/d for four weeks. Phase 3: placebo for two weeks. Phase 4: patients crossed over to opposite treatment from that of phase 2. Spirometry, and diary cards were assessed at beginning and end of phases 2 and 4. HIT was performed at the end of phase 2 and at the beginning and end of phase 4. Twenty patients (eight female and 12 male) completed the study. The evening but not morning PEFR (% predicted) were significantly higher on omeprazole vs placebo (82 +/- 4% SEM vs 79 +/- 4% SEM; p < 0.05). No significant differences were found in FEV1, FVC, histamine bronchial responsiveness and diurnal variation of PEFR between placebo and omeprazole treatments. Similarly, there were no significant differences during placebo and omeprazole periods in day time wheeze, cough, breathlessness, beta 2-agonist use or night time wheeze and breathlessness. Day and night heartburn symptoms were significantly better on omeprazole vs placebo (p < 0.05). Omeprazole 40 mg daily improved evening PEFR in asthma patients with GOR. However, asthma symptoms, inhaled beta 2-agonist use and histamine bronchial responsiveness did not change.Keywords
This publication has 13 references indexed in Scilit:
- Gastroesophageal Reflux-Induced BronchoconstrictionChest, 1995
- Simultaneous tracheal and oesophageal pH measurements in asthmatic patients with gastro-oesophageal reflux.Thorax, 1995
- Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux?Digestive Diseases and Sciences, 1994
- Gastroesophageal Reflux-induced BronchoconstrictionChest, 1994
- Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over studyPublished by Oxford University Press (OUP) ,1994
- Effects of Spontaneous and Simulated Gastroesophageal Reflux on Sleeping AsthmaticsAmerican Review of Respiratory Disease, 1990
- Effects of ranitidine treatment on patients with asthma and a history of gastro-oesophageal reflux: a double blind crossover study.Thorax, 1989
- Gastroesophageal fundoplication for the management of chronic pulmonary disease in childrenThe American Journal of Surgery, 1980
- Bronchial reactivity to inhaled histamine: a method and clinical surveyClinical and Experimental Allergy, 1977
- Intrinsic Asthma in AdultsPublished by American Medical Association (AMA) ,1976